Editorial
Osimertinib for pretreated epidermal growth factor receptor Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Translational Cancer Research
2017;
6
(Suppl 2)
:S235-S238
.
(31 March 2017)
Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients
Translational Cancer Research
2017;
6
(Suppl 2)
:S239-S245
.
(31 March 2017)
Localized prostate cancer genotyping: another step towards personalized therapy
Translational Cancer Research
2017;
6
(Suppl 2)
:S246-S248
.
(31 March 2017)
Poor survival with high-dose chemotherapy and autologous stem cell support in double-hit and double-expressor B-cell lymphomas
Translational Cancer Research
2017;
6
(Suppl 2)
:S249-S253
.
(31 March 2017)
Facing pseudoprogression after radiotherapy in low grade gliomas
Translational Cancer Research
2017;
6
(Suppl 2)
:S254-S258
.
(31 March 2017)
Can we efficiently and safely combine a pan-class I phosphatidylinositol-3-kinase inhibitor with paclitaxel in metastatic breast cancer?
Translational Cancer Research
2017;
6
(Suppl 2)
:S259-S264
.
(31 March 2017)
Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3
Translational Cancer Research
2017;
6
(Suppl 2)
:S265-S269
.
(31 March 2017)
Are all ALK rearrangements created equal?
Translational Cancer Research
2017;
6
(Suppl 2)
:S270-S275
.
(31 March 2017)
Low-frequency ultrasound may improve drug penetration in colonic mucosa
Translational Cancer Research
2017;
6
(Suppl 2)
:S276-S279
.
(31 March 2017)
IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm
Translational Cancer Research
2017;
6
(Suppl 2)
:S280-S285
.
(31 March 2017)
Relevance of the Hedgehog pathway in T-cell acute lymphoblastic leukemia
Translational Cancer Research
2017;
6
(Suppl 2)
:S286-S291
.
(31 March 2017)
A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology
Translational Cancer Research
2017;
6
(Suppl 2)
:S292-S295
.
(31 March 2017)
NLRC3 mediated PI3K-mTOR inhibition takes a toll on colon cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S296-S300
.
(31 March 2017)
Lessons from the NOVA trial: an editorial on results, biomarkers, and patient selection for PARP inhibition in recurrent ovarian cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S301-S305
.
(31 March 2017)
Immunotherapy’s new challenge: identification of predictive biomarkers for tumor response
Translational Cancer Research
2017;
6
(Suppl 2)
:S306-S308
.
(31 March 2017)
Exploring gold nanoparticle interactions with proteins and the tumor microenvironment in biological systems
Translational Cancer Research
2017;
6
(Suppl 2)
:S309-S312
.
(31 March 2017)
Postoperative seizure control in glioma patients with epilepsy
Translational Cancer Research
2017;
6
(Suppl 2)
:S313-S316
.
(31 March 2017)
Normalizing tumoral vessels to treat cancer: an out-of-the-box strategy involving TIE2 pathway
Translational Cancer Research
2017;
6
(Suppl 2)
:S317-S320
.
(31 March 2017)
Rogue one: another faction of the Wnt empire implicated in assisting GBM progression
Translational Cancer Research
2017;
6
(Suppl 2)
:S321-S327
.
(31 March 2017)
The emerging role of Interleukin-21 as an antineoplastic immunomodulatory treatment option
Translational Cancer Research
2017;
6
(Suppl 2)
:S328-S330
.
(31 March 2017)
Current and emerging perspectives on immunotherapy for pancreatic cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S331-S336
.
(31 March 2017)
Glioma-associated epilepsy: toward mechanism-based treatment
Translational Cancer Research
2017;
6
(Suppl 2)
:S337-S341
.
(31 March 2017)
Transient receptor potential, Melastatin-2 (TRPM2) blockade: perspectives on potential novel clinical utility in cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S342-S347
.
(31 March 2017)
Development of predictive liquid biomarkers for response to treatment in small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S348-S352
.
(31 March 2017)
Circulating tumor cells as a liquid biopsy in small cell lung cancer, a future editorial
Translational Cancer Research
2017;
6
(Suppl 2)
:S353-S356
.
(31 March 2017)
Uncertainties of cumulative dose assessment for prostate IMRT
Translational Cancer Research
2017;
6
(Suppl 2)
:S357-S359
.
(31 March 2017)
Adjuvant therapy in renal-cell carcinoma: Is it prime time yet?
Translational Cancer Research
2017;
6
(Suppl 2)
:S360-S362
.
(31 March 2017)
TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
Translational Cancer Research
2017;
6
(Suppl 2)
:S363-S365
.
(31 March 2017)
KDM1 links nuclear GSK3β to epigenetic alterations
Translational Cancer Research
2017;
6
(Suppl 2)
:S366-S368
.
(31 March 2017)
Dividing and conquering the variation among variants in EML4-ALK lung cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S369-S370
.
(31 March 2017)
Will PI3K-targeted therapies for cancer become a reality?
Translational Cancer Research
2017;
6
(Suppl 2)
:S371-S375
.
(31 March 2017)
Editorial to “Palbociclib and letrozole in advanced breast cancer”
Translational Cancer Research
2017;
6
(Suppl 2)
:S376-S379
.
(31 March 2017)
Brigatinib and the new generation of ALK-inhibitors for non-small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S380-S383
.
(31 March 2017)
Unlocking the epigenetic code of T cell exhaustion
Translational Cancer Research
2017;
6
(Suppl 2)
:S384-S387
.
(31 March 2017)
The CXCL12/CXCR4 pathway or the autocrine proliferative loop of the glioblastoma stem cells
Translational Cancer Research
2017;
6
(Suppl 2)
:S388-S390
.
(31 March 2017)
Genomic mutational profiles of metastatic breast cancer: obtaining them early and during the continuum of oncological care
Translational Cancer Research
2017;
6
(Suppl 2)
:S391-S394
.
(31 March 2017)
TRPV1: a channel for mammalian sperm thermotaxis?
Translational Cancer Research
2017;
6
(Suppl 2)
:S395-S398
.
(31 March 2017)
New insights into human testicular germ cell tumors: miR-223-3p gains oncogene function
Translational Cancer Research
2017;
6
(Suppl 2)
:S399-S401
.
(31 March 2017)
Quantification of PD-L1 expression in non-small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S402-S404
.
(31 March 2017)
Translating prognostic prostate cancer gene signatures into the clinic
Translational Cancer Research
2017;
6
(Suppl 2)
:S405-S408
.
(31 March 2017)
Subcellular localization of TRPM2 determines the fate of cancer cells, apoptosis or survival
Translational Cancer Research
2017;
6
(Suppl 2)
:S409-S411
.
(31 March 2017)
Avoiding both the surgically and oncologically futile use of ALPPS
Translational Cancer Research
2017;
6
(Suppl 2)
:S412-S413
.
(31 March 2017)
The subtype-specific role of histone H1.0 in cancer cell differentiation and intratumor heterogeneity
Translational Cancer Research
2017;
6
(Suppl 2)
:S414-S417
.
(31 March 2017)
Genome-based modeling for adjusting radiotherapy dose (GARD)-a significant step toward the future of personalized radiation therapy
Translational Cancer Research
2017;
6
(Suppl 2)
:S418-S420
.
(31 March 2017)
Bevacizumab in small cell lung cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S421-S423
.
(31 March 2017)
When is KRAS or TP53 mutation predictive of response to immunotherapy for lung cancer?
Translational Cancer Research
2017;
6
(Suppl 2)
:S424-S426
.
(31 March 2017)
Mechanisms of the sperm guidance, an essential aid for meeting the oocyte
Translational Cancer Research
2017;
6
(Suppl 2)
:S427-S430
.
(31 March 2017)
Hepatopancreaticoduodenectomy for biliary cancer: operative strategies determine near-zero operative mortality, but tumor biology determines an acceptable long-term outcome
Translational Cancer Research
2017;
6
(Suppl 2)
:S431-S433
.
(31 March 2017)
CXCL12/CXCR4 signaling in glioma stem cells—prospects for therapeutic intervention
Translational Cancer Research
2017;
6
(Suppl 2)
:S434-S437
.
(31 March 2017)
Letter to the Editor
Hidden in plain sight: promising therapeutic targets for glioblastoma lurk within DNA damage response pathways
Translational Cancer Research
2017;
6
(Suppl 2)
:S438-S440
.
(31 March 2017)
Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss
Translational Cancer Research
2017;
6
(Suppl 2)
:S441-S442
.
(31 March 2017)
Differential microRNA expression in epithelial cell populations from human prostate: its relevance to treatment resistance in prostate cancer
Translational Cancer Research
2017;
6
(Suppl 2)
:S443-S445
.
(31 March 2017)
How do the QUARTZ trial results inform future research for patients with brain metastases from non-small cell lung cancer?
Translational Cancer Research
2017;
6
(Suppl 2)
:S446-S447
.
(31 March 2017)
Treatment approach for large-cell neuroendocrine carcinoma of the lung using next-generation sequencing
Translational Cancer Research
2017;
6
(Suppl 2)
:S448-S449
.
(31 March 2017)
Transoral endoscopic thyroidectomy—essentiality of classification
Translational Cancer Research
2017;
6
(Suppl 2)
:S450-S452
.
(31 March 2017)
Disclosure:
This supplement was published without any sponsorship or funding.
